Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and p… Ended

2024-516692-32-00 Refractory metastatic Her2 positive breast cancer 3 2022-05-26
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended

2024-511975-14-00 recurrent/refractory Ewing sarcoma 9 2022-05-26
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJ… Ended

2024-511847-24-00 Biliary tract cancer 4 2022-05-23
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling Ended

2023-508617-16-00 Solid Tumors Dependent on KIT or PDGFRA Signaling 9 2022-05-22
This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B… Ended

2023-504795-20-00 Relapsed/Refractory Aggressive Mature B-cell Neoplasms 3 2022-05-20
A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSC… Ended

2024-514419-93-00 Study to investigate the safety and efficacy of GB1211 9 2022-05-19
RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended

2023-505441-69-00 refractory, advanced gastro-oesophageal cancer 5 2022-05-17
Phase 3 Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for Breast Cancer Patients Ended

2023-508755-39-00 Triple Negative Breast Cancer 5 2022-05-16
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhi… Ended

2024-513716-95-00 Non-Small Cell Lung Cancer, cutaneous melanoma, urothel 1 2022-05-16
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Ended

2023-508954-25-00 Advanced solid tumors (squamous cell carcinoma of the h 7 2022-05-11
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended

2024-511996-13-00 Previously untreated, unresectable, or metastatic melan 5 2022-05-11
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended

2024-512639-58-00 Solid Tumors 7 2022-05-07
A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas Ended

2024-516760-28-00 Metastatic Pancreatic Adenocarcinoma 2 2022-05-04
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low… Ended

2024-514758-65-00 metastatic castration-resistant prostate cancer (mCRPC) 7 2022-05-04
A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with… Ended

2022-502752-31-00 Non-small cell lung cancer 11 2022-04-29
Study of Personalized Neoantigen Specific TCR T cells in the Treatment of Advanced Solid Cancers Ended

2024-518201-18-00 Advanced Solid Cancers 1 2022-04-28
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetux… Ended

2024-513082-39-00 Locally Advanced Head & Neck Squamous Cell Carcinoma 4 2022-04-26
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patien… Ended

2024-513229-22-00 Advanced cutaneous melanoma and Advanced mucosal melano 4 2022-04-21
"OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T… Ended

2023-505097-16-00 Ovarian Neoplasms 4 2022-04-04
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma. Ended

2023-505079-65-00 Multiple myeloma 1 2022-04-01
A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non−Small Cell Lung Cancer who have already received chemo… Ended

2023-503756-27-00 Non-Small Cell Lung Cancer (NSCLC) 4 2022-03-31
SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refra… Ended

2024-515731-29-00 advanced stage hepatocellular carcinoma 4 2022-03-30
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended

2023-508828-35-01 Patients with advanced hormone receptor-positive/HER2- 5 2022-03-28
Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300) Ended

2024-511187-81-00 Colorectal Cancer (CRC) 5 2022-03-28